ArticleTranslational oncology2016

Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.

Anne Winther-Larsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.